General Information

A tablet formulation of DDAVP (desmopressin acetate) has been approved for managing primary nocturnal enuresis in patients age six and over. DDAVP is a synthetic form of vasopressin that has been available in nasal spray since 1989. Vasopressin regulates water balance and urine production.